A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Auteurs

Steven A. Limentani, Mario Campone, Thierry Dorval, Giuseppe Curigliano, Richard de Boer, Charles Vogel, Shane White, Thomas Bachelot, Jean-Luc Canon, Mary Disis, Ahmad Awada, Martine Berlière, Frédéric Amant, Ellis Levine, Wivine Burny, Andrea Callegaro, Pedro Miguel de Sousa Alves, Jamila Louahed, Vincent Brichard, Frédéric F. Lehmann